Nectar Lifesciences: FY26 Audited Results Approved

Nectar Lifesciences Ltd's Board approved the audited standalone and consolidated financial results for the year ended March 31, 2026. The board also approved the re-appointment of Dr. Kuldip Kumar Bhasin and Dr. Indu Pal Kaur as Independent Directors, subject to shareholder approval. The company withdrew the proposal to appoint Alankit Assignments Limited as the Registrar and Transfer Agent (RTA), continuing with KFin Technologies Limited. Amendments were made to Materiality of Information Policy, Related Party Transaction Policy, and Code of Conduct for Prevention of Insider Trading. Key Managerial Personnel were authorized for determining materiality and making disclosures to stock exchanges.